Autor: Violetta Riidas • 30. märts 2009
Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.
VALDOXAN® GRANTED MARKETING AUTHORISATION FOR THE TREATMENT OF MAJOR DEPRESSIVE EPISODES IN EUROPE
Paris, France; 24 February, 2009 –
The European Commission has granted marketing authorisation for Servier’s
Valdoxan® /Thymanax® (agomelatine), the first melatonergic antidepressant for
the treatment of adult patients with major depressive episodes.
“There is still great scope for improved therapies to treat the devastating effects of depression”, said Professor Goodwin from Warneford Hospital, Oxford, United-Kingdom. “Valdoxan is an innovative, new approach to the management of depression that compares favourably to existing treatments. It has proven, sustained efficacy across a wide range of depressed patients, including those who are most severely depressed.”
Valdoxan, one 25 mg tablet taken at bedtime, offers new hope for the 33 million people in Europe suffering from major depressive episode. Valdoxan’s powerful antidepressant efficacy combined with its good safety and tolerability profile is a result of its unique receptor profile. Valdoxan is the first antidepressant with melatonin receptor (MT1) and (MT2) agonist properties and 5-hydroxytryptamine (serotonin) receptor 2C (5-HT2C) antagonist properties. This unique receptor profile of Valdoxan allows for the first time the restoration of the circadian rhythms of depressed patients.
Liitu Meditsiiniuudiste uudiskirjaga!
Liitu Meditsiiniuudiste uudiskirjaga!